Alpha Teknova Q2 revenue $9.6M, down 17% YoY; reaffirms FY2024 guidance $35-38M

Alpha Teknova, Inc.

2024-Q2 EPS reported -$0.33 revenue$18,904,000

Revenue $9.6M, down 17% YoY but up 3% sequentially; Lab Essentials flat, Clinical Solutions down 57%.
Net loss $5.4M ($0.13/share) vs $7.2M prior year; Adjusted EBITDA negative $2.6M.
Gross margin fell to 29.2% from 43.9% due to lower Clinical Solutions revenue and higher overhead.
Raised $15.4M equity in July 2024; cash $18.6M, debt $12.1M; confirms free cash outflow <$18M for FY.
Clinical customers up 26% to 43; launched Express-Tek and RUO+ offerings.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.